Spruce Biosciences (SPRB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $39.65, -4.39% vs the prior close of $41.47.
- Volume 88.43K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SPRB slides 4.4% to $39.65. Closed at $39.65, -4.39% vs the prior close of $41.47. Day range $39.21–$41.53, opened at $41.53.
SPRB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SPRB slides 4.4% to $39.65
- Closed at $39.65, -4.39% vs the prior close of $41.47. Day range $39.21–$41.53, opened at $41.53.
- Volume was 88.43K shares, 1.0x its 50-day average of 84.93K.
- Price is -22.4% vs its 50-day average ($51.10) and -31.2% vs its 200-day average ($57.60).
- 52-week range $38.06–$163.00; today's close sits at 1% of that range, 75.7% below the 52-week high.
Oct 15, 2026 — SPRB jumps 6.4% to $41.47
- Closed at $41.47, +6.39% vs the prior close of $38.98. Day range $39.00–$41.88, opened at $39.00.
- Volume was 63.80K shares, 0.8x its 50-day average of 84.21K.
- Price is -19.1% vs its 50-day average ($51.23) and -28.3% vs its 200-day average ($57.82).
- 52-week range $38.06–$179.95; today's close sits at 2% of that range, 77.0% below the 52-week high.
Oct 14, 2026 — SPRB slides 3.4% to $38.98, a 52-week low, 4 down days in a row
- Closed at $38.98, -3.40% vs the prior close of $40.35. Day range $38.06–$41.44, opened at $40.00.
- Volume was 112.70K shares, 1.4x its 50-day average of 83.22K.
- Price is -24.1% vs its 50-day average ($51.34) and -32.8% vs its 200-day average ($58.02).
- 52-week range $38.06–$188.25; today's close sits at 1% of that range, 79.3% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — SPRB slides 5.9% to $40.35, a 52-week low, 3 down days in a row
- Closed at $40.35, -5.88% vs the prior close of $42.87. Day range $40.19–$42.91, opened at $42.80.
- Volume was 110.60K shares, 1.3x its 50-day average of 81.98K.
- Price is -21.6% vs its 50-day average ($51.48) and -30.7% vs its 200-day average ($58.25).
- 52-week range $40.19–$188.25; today's close sits at 0% of that range, 78.6% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — SPRB dips 2.7% to $42.87
- Closed at $42.87, -2.68% vs the prior close of $44.05. Day range $42.55–$44.94, opened at $44.09.
- Volume was 74.90K shares, 0.9x its 50-day average of 80.95K.
- Price is -16.8% vs its 50-day average ($51.54) and -26.7% vs its 200-day average ($58.47).
- 52-week range $40.33–$199.20; today's close sits at 2% of that range, 78.5% below the 52-week high.
Oct 9, 2026 — SPRB slides 3.3% to $44.05
- Closed at $44.05, -3.27% vs the prior close of $45.54. Day range $42.80–$45.04, opened at $44.84.
- Volume was 83.80K shares, 1.0x its 50-day average of 80.46K.
- Price is -14.5% vs its 50-day average ($51.54) and -24.9% vs its 200-day average ($58.68).
- 52-week range $40.33–$199.20; today's close sits at 2% of that range, 77.9% below the 52-week high.
Oct 8, 2026 — SPRB rises 2.6% to $45.54
- Closed at $45.54, +2.57% vs the prior close of $44.40. Day range $43.34–$45.65, opened at $43.50.
- Volume was 50.80K shares, 0.6x its 50-day average of 80.33K.
- Price is -11.6% vs its 50-day average ($51.52) and -22.6% vs its 200-day average ($58.87).
- 52-week range $40.33–$199.20; today's close sits at 3% of that range, 77.1% below the 52-week high.
Oct 7, 2026 — SPRB jumps 3.8% to $44.40
- Closed at $44.40, +3.77% vs the prior close of $42.78. Day range $42.37–$45.40, opened at $42.56.
- Volume was 59.70K shares, 0.7x its 50-day average of 80.40K.
- Price is -13.7% vs its 50-day average ($51.44) and -24.8% vs its 200-day average ($59.04).
- 52-week range $40.33–$240.00; today's close sits at 2% of that range, 81.5% below the 52-week high.
Oct 6, 2026 — SPRB slides 5.8% to $42.78, a 1-month low
- Closed at $42.78, -5.80% vs the prior close of $45.42. Day range $42.50–$46.72, opened at $45.60.
- Volume was 101.90K shares, 1.3x its 50-day average of 79.72K.
- Price is -16.7% vs its 50-day average ($51.39) and -27.7% vs its 200-day average ($59.20).
- 52-week range $30.03–$240.00; today's close sits at 6% of that range, 82.2% below the 52-week high.
Oct 5, 2026 — SPRB dips 0.6% to $45.42
- Closed at $45.42, -0.63% vs the prior close of $45.71. Day range $43.83–$46.80, opened at $45.51.
- Volume was 65.10K shares, 0.8x its 50-day average of 80.55K.
- Price is -11.6% vs its 50-day average ($51.37) and -23.5% vs its 200-day average ($59.36).
- 52-week range $7.88–$240.00; today's close sits at 16% of that range, 81.1% below the 52-week high.
Oct 2, 2026 — SPRB rises 2.1% to $45.71
- Closed at $45.71, +2.10% vs the prior close of $44.77. Day range $44.12–$47.72, opened at $46.58.
- Volume was 77.20K shares, 1.0x its 50-day average of 79.86K.
- Price is -10.9% vs its 50-day average ($51.32) and -23.2% vs its 200-day average ($59.53).
- 52-week range $7.88–$240.00; today's close sits at 16% of that range, 81.0% below the 52-week high.
SPRB latest news & SEC filings
Every SEC filing by or about SPRB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$16.23M (prior year -$2.07M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$6.68 (prior year -$3.50) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SPRB
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 9, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.26% (largest 7.8%). That is a volatile stock.
- Liquidity: about 84.57K shares (≈$3.35M) trade per day on average.
- 52-week position: $39.65 vs a range of $38.06–$163.00 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:75 on Aug 7, 2025, 1:75 on Aug 5, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Healthcare Partners Llc Parkman sold 232 shares on Oct 6, 2025.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Jul 27, 2026.
- Share count: 2.87M shares outstanding (Aug 10, 2026), +410.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SPRB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 41.53 | 41.53 | 39.21 | 39.65 | 88.43K |
| Oct 15, 2026 | 39.00 | 41.88 | 39.00 | 41.47 | 63.80K |
| Oct 14, 2026 | 40.00 | 41.44 | 38.06 | 38.98 | 112.70K |
| Oct 13, 2026 | 42.80 | 42.91 | 40.19 | 40.35 | 110.60K |
| Oct 12, 2026 | 44.09 | 44.94 | 42.55 | 42.87 | 74.90K |
| Oct 9, 2026 | 44.84 | 45.04 | 42.80 | 44.05 | 83.80K |
| Oct 8, 2026 | 43.50 | 45.65 | 43.34 | 45.54 | 50.80K |
| Oct 7, 2026 | 42.56 | 45.40 | 42.37 | 44.40 | 59.70K |
| Oct 6, 2026 | 45.60 | 46.72 | 42.50 | 42.78 | 101.90K |
| Oct 5, 2026 | 45.51 | 46.80 | 43.83 | 45.42 | 65.10K |
| Oct 2, 2026 | 46.58 | 47.72 | 44.12 | 45.71 | 77.20K |
| Oct 1, 2026 | 48.15 | 49.20 | 44.47 | 44.77 | 79.60K |
| Sep 30, 2026 | 47.78 | 49.95 | 47.76 | 48.58 | 61.30K |
| Sep 29, 2026 | 47.55 | 48.00 | 46.55 | 47.27 | 84.20K |
| Sep 28, 2026 | 48.28 | 48.99 | 47.01 | 47.51 | 42.40K |
| Sep 25, 2026 | 49.22 | 49.31 | 47.54 | 48.72 | 37.20K |
| Sep 24, 2026 | 49.01 | 49.50 | 47.58 | 49.02 | 85.80K |
| Sep 23, 2026 | 50.50 | 50.74 | 45.01 | 49.42 | 174.80K |
| Sep 22, 2026 | 54.05 | 54.98 | 49.23 | 49.99 | 140.70K |
| Sep 21, 2026 | 53.84 | 55.06 | 53.07 | 53.70 | 96.50K |
About Spruce Biosciences
Spruce Biosciences (SPRB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1683553.
SPRB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Percival Barretto-Ko | Director | May 26, 2026 |
| Michael G Grey | Executive Chairman | May 26, 2026 |
| Camilla V Simpson | Director | May 26, 2026 |
| Daniel K Spiegelman | Director | May 26, 2026 |
| Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | Jul 9, 2026 |
| Keli Walbert | Director | May 26, 2026 |
| Douglas Kirk Ways | Interim Chief Medical Officer | Jan 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael G Grey | Executive Chairman | May 26, 2026 |
| Samir M. Gharib | PRESIDENT AND CFO | Dec 17, 2025 |
| Corwin Dale Hooks | Chief Commercial Officer | Mar 9, 2026 |
| Adrian W Quartel | Chief Medical Officer | Jul 29, 2026 |
| Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | Jul 9, 2026 |
| Douglas Kirk Ways | Interim Chief Medical Officer | Jan 21, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 232 | $19.33 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Buy | 256 | $17.91 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 25 | $17.46 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 232 | $19.33 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Buy | 256 | $17.91 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 25 | $17.46 |
| Oct 6, 2025 | Gregory Martinez | Sale | 232 | $19.33 |
| Oct 6, 2025 | Gregory Martinez | Buy | 256 | $17.91 |
| Oct 6, 2025 | Gregory Martinez | Sale | 25 | $17.46 |
| Oct 6, 2025 | Gregory Martinez | Sale | 232 | $19.33 |
| Oct 6, 2025 | Gregory Martinez | Buy | 256 | $17.91 |
| Oct 6, 2025 | Gregory Martinez | Sale | 25 | $17.46 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 232 | $19.33 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Buy | 256 | $17.91 |
| Oct 6, 2025 | Healthcare Partners Llc Parkman | Sale | 25 | $17.46 |
SPRB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-38.97M | -50.83 | $-33.33M |
| Dec 31, 2024 | $4.91M | $-53.04M | -96.40 | $-55.96M |
| Dec 31, 2023 | $10.09M | $-47.92M | -1.24 | $-33.27M |
| Dec 31, 2022 | $0 | $-46.18M | -1.96 | $-41.68M |
| Dec 31, 2021 | — | $-42.29M | -1.81 | $-35.88M |
Latest balance sheet: total assets $102.85M, total liabilities $19.12M, cash $96.30M (as of Jun 30, 2026).
SPRB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $47.07 |
| May 13, 2026 | 8-K Item 2.02 (results) | $57.55 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $62.11 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $73.70 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $115.61 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $8.75 |
| May 6, 2025 | 8-K Item 2.02 (results) | $399.38 |
| Apr 15, 2025 | 8-K Item 2.02 (results) | $742.50 |
| Apr 1, 2025 | 8-K Item 2.02 (results) | $1,507.50 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2,958.75 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SPRB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.